SNCA and Parkinson disease: Parkinson’s disease (PD) is a sophisticated and progressively worsening neurodegenerative condition and characterised by degeneration of dopaminergic neurons in the substantia nigra and accumulation of alpha synuclein in neurons; PD includes motor symptoms, such as tremor, muscle stiffness, reduced mobility and balance, and non-motor features such as cognitive decline, depression and pain [1].